Heparin-binding growth factor pathway and extracellular matrix components

The Heparin-binding growth factor (HBGF) pathway and extracellular matrix (ECM) components represent a complex signaling network rather than a single therapeutic target. This system primarily involves the Fibroblast Growth Factor (FGF) family and Vascular Endothelial Growth Factor (VEGF), which require interaction with heparan sulfate proteoglycans (HSPGs) in the ECM to achieve high-affinity binding with their cognate receptors (Source: PubMed, PMID: 15334664; UniProt, P09038). The ECM acts as a functional scaffold that sequesters these growth factors, protecting them from degradation and regulating their bioavailability and spatial distribution (Source: NCBI Bookshelf, NBK26810). Dysregulation of this axis is heavily implicated in oncogenesis, where it promotes tumor angiogenesis, epithelial-mesenchymal transition, and metastasis (Source: PubMed, PMID: 22439872). While specific components like FGFRs are established drug targets, the broader pathway is modulated by heparin-based anticoagulants and experimental heparin mimetics designed to disrupt growth factor-ECM interactions. Therapeutic development in this area must balance the potent pro-proliferative signaling inhibition with potential systemic toxicities, including bleeding risks and impaired tissue repair (Source: StatPearls, Heparin).

Other names

HBGF pathwayFGF signaling pathwayECM-growth factor axisHeparan sulfate proteoglycan-growth factor complexHeparin-binding growth factor signaling

Disruption of growth factor-extracellular matrix interactions through competitive binding to heparan sulfate sites or direct inhibition of cognate receptor tyrosine kinases.